☆ 4.5 Article

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Cancer statistics in China and United States, 2022: profiles, trends, and determinants

Changfa Xia et al.

Summary: The study compared the latest cancer profiles, trends, and determinants between China and the USA in 2022. China has a higher incidence of lung cancer, while the USA has more cases of breast cancer. Recent years have seen a significant decrease in lung and colorectal cancer rates in the USA, while liver cancer rates have slightly increased. In China, rates for stomach, liver, and esophageal cancer have decreased gradually, but colorectal cancer rates have increased for the whole population.

CHINESE MEDICAL JOURNAL (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021

Fuxing Chen et al.

Summary: The safety profile of the 9-valent human papillomavirus vaccine (9vHPV) was evaluated based on the reporting rate of adverse events following immunization (AEFI) in Zhejiang. The study found a positive signal association between 9vHPV immunization and adverse events such as syncope, encephalitis, sterile abscess, and urticaria. No new emerging safety concerns were identified, but further research is needed to validate and explore adverse reactions associated with 9vHPV.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Add to Collection

Article Clinical Neurology

New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series

Gaia Fanella et al.

Summary: This case report describes three males over the age of 55 who developed new-onset myasthenia gravis (MG) after receiving mRNA SARS-CoV-2 vaccination. The patients presented with ocular and bulbar symptoms shortly after vaccination. The onset of MG ranged from 3 days after the first dose to 10 days after the second dose. Elevated serum AChR antibodies were observed in all patients, and they responded to pyridostigmine. Two out of three patients were successfully treated with IVIG or plasma exchange and long-term immunosuppression.

NEUROLOGICAL SCIENCES (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Laryngeal myasthenia gravis following influenza vaccination: a case report and literature review

Feng Wang et al.

Summary: This case report describes a 58-year-old patient who developed symptoms of laryngeal myasthenia gravis after receiving an influenza vaccine, with significant relief of symptoms after treatment. Further research is needed to assess the relationship between the influenza vaccine and neurological complications in myasthenia gravis.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Article Health Care Sciences & Services

Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study

Jingshan Chen et al.

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2020)

Add to Collection

Article Clinical Neurology

Myasthenia gravis following human papillomavirus vaccination: a case report

Ji Yeon Chung et al.

BMC NEUROLOGY (2018)

Add to Collection

Review Clinical Neurology

Vaccines and multiple sclerosis: a systematic review

Mia Topsoe Mailand et al.

JOURNAL OF NEUROLOGY (2017)

Add to Collection

Article Immunology

Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France

Sara Miranda et al.

VACCINE (2017)

Add to Collection

Review Biotechnology & Applied Microbiology

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

Julianne Gee et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)

Add to Collection

Review Clinical Neurology

Myasthenia gravis: subgroup classification and therapeutic strategies

Nils Erik Gilhus et al.

LANCET NEUROLOGY (2015)

Add to Collection

Letter Clinical Neurology

Autoimmune neuromyotonia following human papilloma virus vaccination

Chiara Cerami et al.

MUSCLE & NERVE (2013)

Add to Collection

Editorial Material Clinical Neurology

NEUROMYELITIS OPTICA FOLLOWING HUMAN PAPILLOMAVIRUS VACCINATION

Til Menge et al.

NEUROLOGY (2012)

Add to Collection

Review Immunology

Human Papillomavirus Vaccines - Immune Responses

Margaret Stanley et al.

VACCINE (2012)

Add to Collection

Review Public, Environmental & Occupational Health

The Incidence of Myasthenia Gravis: A Systematic Literature Review

Anita McGrogan et al.

NEUROEPIDEMIOLOGY (2010)

Add to Collection

Article Clinical Neurology

Encefalomielitis aguda diseminada con lesiones tumefactas tras vacunación contra el virus del papiloma humano

Z. Mendoza Plasencia et al.

NEUROLOGIA (2010)

Add to Collection

Review Medicine, General & Internal

Vaccination and autoimmune disease: what is the evidence?

DC Wraith et al.

LANCET (2003)

Add to Collection

Letter Pharmacology & Pharmacy

Myasthenia gravis after hepatitis B vaccine

B Louzir et al.

THERAPIE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.